New Once‑Daily Pill Nearly Doubles Survival for Late‑Stage Pancreatic Cancer Patients

A breakthrough oral drug, daraxonrasib, significantly extended survival and reduced the risk of death compared to chemotherapy in a major Phase 3 trial for late‑stage pancreatic cancer.